Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokKorai 1. fázis

Impact of Nrf2 Activation on Macrovascular, Microvascular & Leg Function & Walking Capacity in Peripheral Artery Disease

A legfontosabb adatok

Ki végzi
University of Nebraska
Hol
Omaha (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Fázis
Korai 1. fázis
Résztvevők
20 fő, tervezett
Kezdés
2024. nov. 14.
Várható befejezés
2026. dec.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Vumerity
  • Placebo
A regiszteradat frissítve
2026. június 24.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for adults with peripheral artery disease (narrowed leg arteries) who get leg pain when walking. It is also looking for people of similar age without this disease as a comparison group.

Életkor
50-75 years
Nem
Men and women. Women must be past menopause (no periods for more than 24 months).
A betegség stádiuma
People with the disease: Fontaine stage II-III, with a history of leg pain during exercise (claudication). Comparison group: no sign of artery blockage (ankle-brachial index > 0.90).
Korábbi kezelés
People cannot join if they are currently taking dimethyl fumarate.
Biomarker vagy leletérték
Normal kidney function (estimated glomerular filtration rate >= 60 mL/min), normal liver tests and blood counts within set ranges, or stable values within the last 6 months.

A részvétel fő kizáró okai

  • Pain at rest, ulcers, gangrene or tissue loss in the foot (Fontaine stage IV)
  • Walking limited by conditions other than the artery disease
  • Pregnant or breastfeeding
  • Multiple sclerosis, psoriasis, or gut disorders such as moderate IBS or Crohn's disease
  • Allergy to diroximel fumarate, dimethyl fumarate or any ingredient of VUMERITY

A regiszter feltételei, szó szerint

Mind a 37 feltétel megnézéseKevesebb

Ki vehet részt

  • Peripheral artery disease (PAD) participants:
  • Able to provide written informed consent
  • 50-75 years of age
  • Diagnosed as Fontaine stage II-III
  • History of exercise-induced claudication
  • Females must be postmenopausal (cessation of menses for > 24 months)
  • Normal renal function (serum creatinine-estimated glomerular filtration rate >= 60 mL/min) or evidence of stable renal function within the last 6 months
  • Normal hepatic function (alanine transaminase < 87.5 U/L, alkaline phosphatase < 260 U/L, total bilirubin 1.8 mg/dL) or evidence of stable hepatic function within the last 6 months
  • Complete blood count:; Females: red blood cell 4-5 trillion cells/L, hemoglobin 12-15 g/dL, hematocrit 34-45%, white blood cell count 3-10 billion cells/L, platelet count 160-380 billion/L, and normal lymphocyte count > 700 million lymphocytes/L, or evidence of stable blood counts within the last 6 months; Males: red blood cell 4-6 trillion cells/L, hemoglobin 13-17 g/dL, hematocrit 38-49%, white blood cell count 3-10 billion cells/L, platelet count 135-320 billion/L, and normal lymphocyte count > 700 million lymphocytes/L, or evidence of stable blood counts within the last 6 months; Age-matched control participants:
  • Able to provide written informed consent
  • 50-75 years of age
  • No evidence of peripheral occlusive disease (ankle-brachial index > 0.90)
  • Females must be postmenopausal (cessation of menses for > 24 months)
  • Normal renal function (serum creatinine-estimated glomerular filtration rate >= 60 mL/min), or evidence of stable renal function within the last 6 months
  • Normal hepatic function (alanine transaminase < 87.5 U/L, alkaline phosphatase < 260 U/L, total bilirubin 1.8 mg/dL ), or evidence of stable hepatic function within the last 6 months
  • Complete blood count:; Females: red blood cell 4-5 trillion cells/L, hemoglobin 12-15 g/dL, hematocrit 34-45%, white blood cell count 3-10 billion cells/L, platelet count 160-380 billion/L, and normal lymphocyte count > 700 million lymphocytes/L; Males: red blood cell 4-6 trillion cells/L, hemoglobin 13-17 g/dL, hematocrit 38-49%, white blood cell count 3-10 billion cells/L, platelet count 135-320 billion/L, and normal lymphocyte count > 700 million lymphocytes/L, or evidence of stable blood counts within the last 6 months

Ki nem vehet részt

  • Concomitant use of dimethyl fumarate
  • Peripheral artery disease (PAD) participants:
  • Acute lower extremity ischemic event secondary to thromboembolic disease or acute trauma
  • Limited walking capacity from conditions other than PAD
  • Diagnosis of gastrointestinal disorders (e.g., moderate IBS, Crohn's disease, etc
  • Hypersensitivity to diroximel fumarate, dimethyl fumarate, or to any of the excipients of VUMERITY
  • Blood work and medical history NOT demonstrating:; Normal renal function (serum creatinine-estimated glomerular filtration rate >> 60 mL/min); Normal hepatic function (alanine transaminase 0-35 IU/L, alkaline phosphatase 30-120 IU/L, total bilirubin 2-17 micromoles/L),
  • Complete blood count NOT within ranges:; Females: red blood cell 4-5 trillion cells/L, hemoglobin 12-15 g/dL, hematocrit 34-45%, white blood cell count 3-10 billion cells/L, platelet count 160-380 billion/L, and normal lymphocyte count 1-4.8 billion lymphocytes/L; Males: red blood cell 4-6 trillion cells/L, hemoglobin 13-17 g/dL, hematocrit 38-49%, white blood cell count 3-10 billion cells/L, platelet count 135-320 billion/L, and normal lymphocyte count 1-4.8 billion lymphocytes/L; Age-matched control participants:
  • Renal function not within normal ranges (serum creatinine-estimated glomerular filtration rate >> 60 mL/min)
  • Hepatic function not within normal ranges (alanine transaminase 0-35 IU/L, alkaline phosphatase 30-120 IU/L, total bilirubin 2-17 micromoles/L)
  • Complete blood count NOT within ranges:; Females: red blood cell 4-5 trillion cells/L, hemoglobin 12-15 g/dL, hematocrit 34-45%, white blood cell count 3-10 billion cells/L, platelet count 160-380 billion/L, and normal lymphocyte count 1-4.8 billion lymphocytes/L; Males: red blood cell 4-6 trillion cells/L, hemoglobin 13-17 g/dL, hematocrit 38-49%, white blood cell count 3-10 billion cells/L, platelet count 135-320 billion/L, and normal lymphocyte count 1-4.8 billion lymphocytes/L
  • • Pain at rest and/or tissue loss due to PAD (Fontaine stage IV PAD)
  • No physical exam to assess exercise limitations in the past year
  • Currently pregnant or nursing
  • Diagnosis of multiple sclerosis or psoriasis
  • Ulcers, gangrene, or necrosis of the foot (Fontaine stage IV PAD)
  • Positive diagnosis of PAD
  • No physical exam to assess exercise limitations in the past year
  • Any exercise limitations as determined at last physical exam
  • Limited walking capacity from musculoskeletal injury
  • Currently pregnant or nursing

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 50 és 75 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • University of Nebraska OmahaOmaha, Egyesült ÁllamokContact: Gwenael Layec, PhDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Peripheral artery disease (PAD) is associated with elevated oxidative stress, and oxidative stress has been implicated as the cause of reduced endothelial reactivity in individuals with PAD. Endothelial function is important because the endothelium contributes to the dilation of arteries during exercise, thereby implicating impaired endothelial function as a mechanism contributing to exacerbated exercise-induced ischemia. Therefore, the purpose of this study is to test the hypothesis that acute exogenous diroximel fumarate (Vumerity) intake will improve antioxidant capacity, thereby reducing oxidative stress and improving vascular function and walking capacity in those with PAD. During this study, participants will be administered diroximel fumarate or a placebo, and the acute effects of diroximel fumarate on vascular function and walking capacity will be assessed. Vascular function and walking capacity will be assessed with flow-mediated dilation, arterial stiffness, head-up tilt test, blood biomarkers, near-infrared spectroscopy, and a treadmill test. There will be a follow-up visit to assess blood work after diroximel fumarate.

A vizsgálat 4 csoportja

  • Control: Vumerity intake, then PlaceboA vizsgált kezelés

    Participants will receive a single dose of VUMERITY (diroximal fumarate, 462mg). After a minimum period of 7 days, they will then receive a single dose of the placebo (microcrystalline cellulose, 462 mg).

    Kezelés: Vumerity és Placebo

  • Control: Placebo intake, then VumerityPlacebo, összehasonlításként

    Participants will receive a single dose of placebo (microcrystalline cellulose, 462 mg). After a minimum period of 7 days, they will then receive a single dose of VUMERITY (diroximal fumarate, 462mg).

    Kezelés: Vumerity és Placebo

  • PAD: Vumerity intake, then PlaceboA vizsgált kezelés

    Participants with peripheral artery disease (PAD) will receive a single dose of VUMERITY (diroximal fumarate, 462mg). After a minimum period of 7 days, they will then receive a single dose of the placebo (microcrystalline cellulose, 462 mg).

    Kezelés: Vumerity és Placebo

  • PAD: Placebo intake, then VumerityPlacebo, összehasonlításként

    Participants with peripheral artery disease (PAD) will receive a single dose of placebo (microcrystalline cellulose, 462 mg). After a minimum period of 7 days, they will then receive a single dose of VUMERITY (diroximal fumarate, 462mg).

    Kezelés: Vumerity és Placebo

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Impact of Nrf2 Activation on Macrovascular Function, Microvascular Function, Leg Function, and Walking Capacity in Patients With Peripheral Artery Disease
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
Kérdések a feltételekről
Forrás: NCT06319339: ki vehet részt
A regiszteradat frissítve
2026. június 24.